One-third of target group now vaccinated against monkeypox 10,440 monkeypox vaccinations have already been administered in the Netherlands in the last few weeks. That represents about one-third of the target group currently eligible to get the vaccine against monkeypox. Science Photo Library / ANP
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
National Heatwave Plan no longer in operation as of 17 August 2022 As of Wednesday, 17 August 2022, the National Heatwave Plan is no longer in operation. Although the period of persistent heat is over, temperatures will remain high over the coming days.
National Heatwave Plan to be activated on 10 August After consulting the Royal Netherlands Meteorological Institute (KNMI), RIVM has decided to activate the National Heatwave Plan in all Dutch provinces as of 10 August 2022.
Update on RIVM report “Silicone breast implants in the Netherlands”, State of Affairs October 2017 In June 2016, RIVM published the results of a study on breast implants in the Netherlands.
RIVM to contribute to new Horizon2020 project on oceans and human health across Europe A new EU Horizon2020 project Seas, Oceans and Public Health in Europe (SOPHIE) will explore the complex interplay between the health of the marine environment and that of humans.
Dutch collaboration in One Health European Joint Programme (EJP) RIVM, Wageningen Bioveterinary Research (WBVR) and the Netherlands Centre for One Health (NCOH) are involved in a recently granted One Health European Joint Programme which will start in January 20
Survey health complaints of women with a silicone breast implant This report provides a broad overview of the health complaints experienced by women with silicone breast implants in the Netherlands.
Efficiency and transparency of clinical drug trials must improve The efficiency and transparency of clinical drug trials in the Netherlands must improve. That concludes Sander van den Bogert in his PhD thesis ‘Trials & Tribulations.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.